Synthesis, biological evaluation, and molecular docking studies of novel 3-aryl-5-(alkyl-thio)-1H-1,2,4-triazoles derivatives targeting Mycobacterium tuberculosis. 2017

Navnath D Rode, and Amol D Sonawane, and Laxman Nawale, and Vijay M Khedkar, and Ramesh A Joshi, and Anjali P Likhite, and Dhiman Sarkar, and Rohini R Joshi
Division of Organic Chemistry, CSIR-National Chemical Laboratory, Pune, India.

A small library of new 3-aryl-5-(alkyl-thio)-1H-1,2,4-triazoles was synthesized and screened for the antimycobacterial potency against Mycobacterium tuberculosis H37 Ra strain and Mycobacterium bovis BCG both in active and dormant stage. Among the synthesized library, 25 compounds exhibited promising anti-TB activity in the range of IC50 0.03-5.88 μg/ml for dormant stage and 20 compounds in the range of 0.03-6.96 μg/ml for active stage. Their lower toxicity (>100 μg/ml) and higher selectivity (SI = >10) against all cancer cell lines screened make them interesting compounds with potential antimycobacterial effects. Furthermore, to rationalize the observed biological activity data and to establish a structural basis for inhibition of M. tuberculosis, the molecular docking study was carried out against a potential target MTB CYP121 which revealed a significant correlation between the binding score and biological activity for these compounds. Cytotoxicity and in vivo pharmacokinetic studies suggested that 1,2,4-triazole analogues have an acceptable safety index, in vivo stability and bio-availability.

UI MeSH Term Description Entries
D009163 Mycobacterium bovis The bovine variety of the tubercle bacillus. It is called also Mycobacterium tuberculosis var. bovis. BCG,Calmette-Guerin Bacillus
D009169 Mycobacterium tuberculosis A species of gram-positive, aerobic bacteria that produces TUBERCULOSIS in humans, other primates, CATTLE; DOGS; and some other animals which have contact with humans. Growth tends to be in serpentine, cordlike masses in which the bacilli show a parallel orientation. Mycobacterium tuberculosis H37Rv
D002470 Cell Survival The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability. Cell Viability,Cell Viabilities,Survival, Cell,Viabilities, Cell,Viability, Cell
D003577 Cytochrome P-450 Enzyme System A superfamily of hundreds of closely related HEMEPROTEINS found throughout the phylogenetic spectrum, from animals, plants, fungi, to bacteria. They include numerous complex monooxygenases (MIXED FUNCTION OXYGENASES). In animals, these P-450 enzymes serve two major functions: (1) biosynthesis of steroids, fatty acids, and bile acids; (2) metabolism of endogenous and a wide variety of exogenous substrates, such as toxins and drugs (BIOTRANSFORMATION). They are classified, according to their sequence similarities rather than functions, into CYP gene families (>40% homology) and subfamilies (>59% homology). For example, enzymes from the CYP1, CYP2, and CYP3 gene families are responsible for most drug metabolism. Cytochrome P-450,Cytochrome P-450 Enzyme,Cytochrome P-450-Dependent Monooxygenase,P-450 Enzyme,P450 Enzyme,CYP450 Family,CYP450 Superfamily,Cytochrome P-450 Enzymes,Cytochrome P-450 Families,Cytochrome P-450 Monooxygenase,Cytochrome P-450 Oxygenase,Cytochrome P-450 Superfamily,Cytochrome P450,Cytochrome P450 Superfamily,Cytochrome p450 Families,P-450 Enzymes,P450 Enzymes,Cytochrome P 450,Cytochrome P 450 Dependent Monooxygenase,Cytochrome P 450 Enzyme,Cytochrome P 450 Enzyme System,Cytochrome P 450 Enzymes,Cytochrome P 450 Families,Cytochrome P 450 Monooxygenase,Cytochrome P 450 Oxygenase,Cytochrome P 450 Superfamily,Enzyme, Cytochrome P-450,Enzyme, P-450,Enzyme, P450,Enzymes, Cytochrome P-450,Enzymes, P-450,Enzymes, P450,Monooxygenase, Cytochrome P-450,Monooxygenase, Cytochrome P-450-Dependent,P 450 Enzyme,P 450 Enzymes,P-450 Enzyme, Cytochrome,P-450 Enzymes, Cytochrome,Superfamily, CYP450,Superfamily, Cytochrome P-450,Superfamily, Cytochrome P450
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000995 Antitubercular Agents Drugs used in the treatment of tuberculosis. They are divided into two main classes: "first-line" agents, those with the greatest efficacy and acceptable degrees of toxicity used successfully in the great majority of cases; and "second-line" drugs used in drug-resistant cases or those in which some other patient-related condition has compromised the effectiveness of primary therapy. Anti-Tuberculosis Agent,Anti-Tuberculosis Agents,Anti-Tuberculosis Drug,Anti-Tuberculosis Drugs,Antitubercular Agent,Antitubercular Drug,Tuberculostatic Agent,Tuberculostatic Agents,Antitubercular Drugs,Agent, Anti-Tuberculosis,Agent, Antitubercular,Agent, Tuberculostatic,Anti Tuberculosis Agent,Anti Tuberculosis Agents,Anti Tuberculosis Drug,Anti Tuberculosis Drugs,Drug, Anti-Tuberculosis,Drug, Antitubercular
D001665 Binding Sites The parts of a macromolecule that directly participate in its specific combination with another molecule. Combining Site,Binding Site,Combining Sites,Site, Binding,Site, Combining,Sites, Binding,Sites, Combining
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D014230 Triazoles Heterocyclic compounds containing a five-membered ring with two carbon atoms and three nitrogen atoms with the molecular formula C2H3N3. Triazole
D045744 Cell Line, Tumor A cell line derived from cultured tumor cells. Tumor Cell Line,Cell Lines, Tumor,Line, Tumor Cell,Lines, Tumor Cell,Tumor Cell Lines

Related Publications

Navnath D Rode, and Amol D Sonawane, and Laxman Nawale, and Vijay M Khedkar, and Ramesh A Joshi, and Anjali P Likhite, and Dhiman Sarkar, and Rohini R Joshi
February 2021, Molecular diversity,
Navnath D Rode, and Amol D Sonawane, and Laxman Nawale, and Vijay M Khedkar, and Ramesh A Joshi, and Anjali P Likhite, and Dhiman Sarkar, and Rohini R Joshi
November 2019, Archiv der Pharmazie,
Navnath D Rode, and Amol D Sonawane, and Laxman Nawale, and Vijay M Khedkar, and Ramesh A Joshi, and Anjali P Likhite, and Dhiman Sarkar, and Rohini R Joshi
October 1998, Arzneimittel-Forschung,
Navnath D Rode, and Amol D Sonawane, and Laxman Nawale, and Vijay M Khedkar, and Ramesh A Joshi, and Anjali P Likhite, and Dhiman Sarkar, and Rohini R Joshi
August 2022, Chemical biology & drug design,
Navnath D Rode, and Amol D Sonawane, and Laxman Nawale, and Vijay M Khedkar, and Ramesh A Joshi, and Anjali P Likhite, and Dhiman Sarkar, and Rohini R Joshi
April 2022, International journal of molecular sciences,
Navnath D Rode, and Amol D Sonawane, and Laxman Nawale, and Vijay M Khedkar, and Ramesh A Joshi, and Anjali P Likhite, and Dhiman Sarkar, and Rohini R Joshi
January 2023, Advances and applications in bioinformatics and chemistry : AABC,
Navnath D Rode, and Amol D Sonawane, and Laxman Nawale, and Vijay M Khedkar, and Ramesh A Joshi, and Anjali P Likhite, and Dhiman Sarkar, and Rohini R Joshi
July 1987, Il Farmaco; edizione scientifica,
Navnath D Rode, and Amol D Sonawane, and Laxman Nawale, and Vijay M Khedkar, and Ramesh A Joshi, and Anjali P Likhite, and Dhiman Sarkar, and Rohini R Joshi
February 2018, Computational biology and chemistry,
Navnath D Rode, and Amol D Sonawane, and Laxman Nawale, and Vijay M Khedkar, and Ramesh A Joshi, and Anjali P Likhite, and Dhiman Sarkar, and Rohini R Joshi
October 1971, Journal of medicinal chemistry,
Navnath D Rode, and Amol D Sonawane, and Laxman Nawale, and Vijay M Khedkar, and Ramesh A Joshi, and Anjali P Likhite, and Dhiman Sarkar, and Rohini R Joshi
September 2021, International journal of molecular sciences,
Copied contents to your clipboard!